Literature DB >> 2621519

Long-term follow-up study of patients with cholangitis after successful Kasai operation in biliary atresia: selection of recipients for liver transplantation.

N Ohkohchi1, T Chiba, R Ohi, S Mori.   

Abstract

Since the introduction of cyclosporine A, liver transplantation has become accepted as the therapy for end-stage liver disease. However, there are no definite criteria for liver replacement in biliary atresia. We investigated (a) the survival rate after hepatic portoenterostomy (n = 131), (b) liver function tests in fatal cases after an initially successful hepatic portoenterostomy (n = 9), and (c) liver function tests in the patients with episodes of cholangitis after a successful surgical treatment (n = 8). Patients with persisting jaundice after the surgery cannot be expected to survive long, and therefore they definitely should undergo liver transplantation. When total bilirubin concentration was above 10 mg/dl in patients with cholangitis after a successful operation, conservative therapy had almost no effect. Therefore, patients with total bilirubin levels above 10 mg/dl should be considered for liver transplantation. Of the liver function tests, only total bilirubin was reliable as a marker for hepatic failure in the end stage of biliary atresia. Prolongation of thrombo test and episodes of gastrointestinal bleeding also were used in selection of patients for liver replacement.

Entities:  

Mesh:

Year:  1989        PMID: 2621519     DOI: 10.1097/00005176-198911000-00003

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  7 in total

Review 1.  Liver disease in infancy: a 20 year perspective.

Authors:  G Mieli-Vergani; E R Howard; A P Mowat
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Jaundice at 14 days of age: exclude biliary atresia.

Authors:  M Hussein; E R Howard; G Mieli-Vergani; A P Mowat
Journal:  Arch Dis Child       Date:  1991-10       Impact factor: 3.791

3.  Intravenous immunoglobulin for the treatment of intractable cholangitis after Kasai portoenterostomy in biliary atresia patients.

Authors:  Dandan Li; Pei Wang; Ying He; Chunlei Jiao; Didi Zhuansun; Nannan Wei; Jixin Yang; Jiexiong Feng
Journal:  Pediatr Surg Int       Date:  2018-02-21       Impact factor: 1.827

4.  Bone marrow mononuclear stem cell infusion improves biochemical parameters and scintigraphy in infants with biliary atresia.

Authors:  Shilpa Sharma; Lalit Kumar; Sujata Mohanty; Rakesh Kumar; S Datta Gupta; Devendra K Gupta
Journal:  Pediatr Surg Int       Date:  2011-01       Impact factor: 1.827

Review 5.  Biliary atresia.

Authors:  Giorgina Mieli-Vergani; Diego Vergani
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

6.  Endoscopic retrograde cholangiopancreatography in infantile cholestasis.

Authors:  M L Wilkinson; G Mieli-Vergani; C Ball; B Portmann; A P Mowat
Journal:  Arch Dis Child       Date:  1991-01       Impact factor: 3.791

7.  Predictors of Successful Kasai Portoenterostomy and Survival with Native Liver at 2 Years in Infants with Biliary Atresia.

Authors:  Ruchika Kumar; Bikrant B Lal; Vikrant Sood; Rajeev Khanna; Senthil Kumar; Kishore G S Bharathy; Seema Alam
Journal:  J Clin Exp Hepatol       Date:  2018-10-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.